Sanofi, Regeneron expand 2015 immuno-oncology agreement

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) expanded a 2015 immuno-oncology deal to increase and accelerate investment in the clinical development of anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) for cancer

Read the full 305 word article

User Sign In